1 April 2025 false No description of principal activity Taxfiler 2024.6 14760845business:PrivateLimitedCompanyLtd2025-04-012026-03-31 147608452025-03-31 147608452025-04-012026-03-31 14760845business:AuditExempt-NoAccountantsReport2025-04-012026-03-31 14760845business:AbridgedAccounts2025-04-012026-03-31 147608452026-03-31 14760845business:Director12025-04-012026-03-31 14760845business:Director22025-04-012026-03-31 147608452025-03-31 14760845core:WithinOneYear2026-03-31 14760845core:WithinOneYear2025-03-31 14760845core:AfterOneYear2026-03-31 14760845core:AfterOneYear2025-03-31 14760845core:CapitalContributionReservecore:PreviouslyStatedAmount2026-03-31 14760845core:CapitalContributionReservecore:PreviouslyStatedAmount2025-03-31 14760845core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2026-03-31 14760845core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2025-03-31 14760845core:PreviouslyStatedAmount2026-03-31 14760845core:PreviouslyStatedAmount2025-03-31 14760845business:SmallEntities2025-04-012026-03-31 14760845countries:EnglandWales2025-04-012026-03-31 147608452024-04-012025-03-31 iso4217:GBP xbrli:pure
Company Registration No. 14760845 (England and Wales)
Bear Cross Pharma Ltd Unaudited accounts for the year ended 31 March 2026
Bear Cross Pharma Ltd Unaudited accounts Contents
Page
- 2 -
Bear Cross Pharma Ltd Company Information for the year ended 31 March 2026
Directors
Jean Okutu Antwi Isaac Ababio Antwi
Company Number
14760845 (England and Wales)
Accountants
ISAAC A ANTWI 17 HASTINGS ROAD BOURNEMOUTH DORSET BH8 0HN
- 3 -
Bear Cross Pharma Ltd Statement of financial position as at 31 March 2026
2026 
2025 
Notes
£ 
£ 
Fixed assets
Intangible assets
480,000 
- 
Tangible assets
2,850 
2,850 
482,850 
2,850 
Current assets
Inventories
28,407 
- 
Debtors
45,023 
854 
Cash at bank and in hand
20,829 
23,374 
94,259 
24,228 
Creditors: amounts falling due within one year
(177,268)
(650,750)
Net current liabilities
(83,009)
(626,522)
Total assets less current liabilities
399,841 
(623,672)
Creditors: amounts falling due after more than one year
382,874 
- 
Net assets/(liabilities)
782,715 
(623,672)
Capital and reserves
Capital contribution reserve
1,462,076 
- 
Profit and loss account
(679,361)
(623,672)
Shareholders' funds
782,715 
(623,672)
For the year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
The members have agreed to the preparation of abridged accounts for the year in accordance with Section 444(2A).
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 31 August 2026 and were signed on its behalf by
Jean Okutu Antwi Director Company Registration No. 14760845
- 4 -
Bear Cross Pharma Ltd Notes to the Accounts for the year ended 31 March 2026
1
Statutory information
Bear Cross Pharma Ltd is a private company, limited by shares, registered in England and Wales, registration number 14760845.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Intangible fixed assets
Intangible fixed assets (including purchased goodwill and patents) are included at cost less accumulated amortisation.
4
Intangible fixed assets
Total 
£ 
Cost
At 1 April 2025
- 
Additions
480,000 
At 31 March 2026
480,000 
Amortisation
At 1 April 2025
- 
At 31 March 2026
- 
Net book value
At 31 March 2026
480,000 
5
Tangible fixed assets
Total 
£ 
Cost or valuation
At 1 April 2025
2,850 
At 31 March 2026
2,850 
Depreciation
At 31 March 2026
- 
Net book value
At 31 March 2026
2,850 
At 31 March 2025
2,850 
- 5 -
Bear Cross Pharma Ltd Notes to the Accounts for the year ended 31 March 2026
6
Average number of employees
During the year the average number of employees was 5 (2025: 0).
- 6 -